Commentary: Zaltrapped –Sanofi’s colder calculations of a drug’s worth
This article was originally published in Scrip
Sanofi’s decision to halve the net price of its newly approved VEGF inhibitor Zaltrap for may have less to do with public condemnation by individual high profile clinical researchers and much more to with a localized outbreak of sensitive urgent commercial knowledge syndrome.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.